XORTX Therapeutics Inc.
XRTX
$0.87
-$0.1026-10.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 546.60K | 834.60K | 513.80K | 516.60K | 524.40K |
| Depreciation & Amortization | 25.90K | 33.00K | 32.10K | 24.40K | 16.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 607.30K | 935.40K | 619.50K | 675.10K | 1.11M |
| Operating Income | -607.30K | -935.40K | -619.50K | -675.10K | -1.11M |
| Income Before Tax | -587.00K | 170.10K | -3.02M | 2.70M | -1.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -587.00K | 170.10K | -3.02M | 2.70M | -1.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -587.00K | 170.10K | -3.02M | 2.70M | -1.33M |
| EBIT | -607.30K | -935.40K | -619.50K | -675.10K | -1.11M |
| EBITDA | -597.20K | -887.90K | -605.70K | -667.10K | -1.09M |
| EPS Basic | -0.20 | 0.06 | -1.24 | 1.35 | -0.67 |
| Normalized Basic EPS | -0.13 | 0.04 | -0.78 | 0.84 | -0.42 |
| EPS Diluted | -0.20 | 0.06 | -1.24 | 1.34 | -0.67 |
| Normalized Diluted EPS | -0.13 | 0.04 | -0.78 | 0.84 | -0.42 |
| Average Basic Shares Outstanding | 2.90M | 2.90M | 2.43M | 2.00M | 2.00M |
| Average Diluted Shares Outstanding | 2.90M | 2.90M | 2.43M | 2.00M | 2.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
